Quotables
"Without question, the greatest invention in the history of mankind is beer. Oh, I grant you that the wheel was also a fine invention, but the wheel does not go nearly as well with pizza."
Dave Barry
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8114958 | Amylin family peptides The present invention relates to obesity related polypeptides (ORPs), related nucleic acids, expression constructs, host cells, and processes production of the obesity related polypeptides. The ORPs of the invention include one or more amino acid sequence modificati... | 02/14/2012 |
| 8076291 | Treatment for obesity The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like. ... | 12/13/2011 |
| 8030269 | Calcitonin drug-oligomer conjugates, and uses thereof Calcitonin drug-oligomer conjugates that include a calcitonin drug coupled to an oligomer including a single polyalkylene glycol moiety consisting of between 4 and 10 polyalkylene glycol subunits are disclosed. Pharmaceutical compositions including such conjugates a... | 10/04/2011 |
| 7812120 | Nasal calcitonin formulations containing chlorobutanol Compositions suitable for intranasal administration containing calcitonin, chlorobutanol, a pH of about 3.5, and sodium chloride, and an intranasal spray and a pharmaceutical delivery device thereof. ... | 10/12/2010 |
| 7338770 | Human procalcitonin and the preparation and use thereof The invention relates to human procalcitonin and the preparation and use thereof. In particular, a process for preparing human procalcitonin is described wherein a gene coding for a polypeptide comprising the amino acid sequence of human procalcitonin is inserted in... | 03/04/2008 |
| 7312196 | Formulations for amylin agonist peptides The present invention is concerned with a pharmaceutical formulation comprising an amylin agonist and optionally a buffer, a tonicifier or stabilizer, and a preservative in a container, for example, a vial, prefilled cartridge, prefilled syringe or disposable pen. T... | 12/25/2007 |
| 7204822 | Intranasal delivery system This invention relates to apparatus and methods of delivering various compositions including medicaments to a variety of targets. The invention includes a dose administrator (1) which may be used for intranasal delivery of compositions or medicaments, such as... | 04/17/2007 |
| 7087739 | Nucleic acid encoding recombinant salmon calcitonin, expression vector thereof, and method for producing recombinant salmon calcitonin therewith Nucleic acid encoding recombinant salmon calcitonin, expression vector thereof, and method for producing recombinant salmon calcitonin therewith. The nucleic acid encoding recombinant salmon calcitonin comprises the sequence of SEQ ID No. 2. ... | 08/08/2006 |
| 7084121 | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same A mixture of conjugates in which each conjugate in the mixture comprises a calcitonin drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may lower serum calcium levels in a subject by 10, 15 or even 20 percent or more. M... | 08/01/2006 |
| 7030081 | Muteins of the CGRP 1-7 peptide fragment and use thereof as nicotinic neuronal receptor enhancers Muteins of the Ser-Cys-Asn-Thr-Ala-Thr-Cys sequence from the N-terminal 1-7 fragment of the CGRP peptide, possessing an enhancing action on the activation of neuronal nicotinic receptors, their pharmaceutical compositions containing the same and their use for the po... | 04/18/2006 |
| 6969702 | Compounds and methods for increasing neurogenesis The invention is directed to methods of promoting neurogenesis by contacting neuronal tissue with neurogenesis increasing agents. Novel methods for treating neurological disorders using neurogenesis increasing agents are disclosed. ... | 11/29/2005 |
| 6929797 | Targeted therapeutic delivery of vitamin D compounds The present invention is directed to a conjugate which includes at least one vitamin D moiety thereof and at least one targeting molecule moiety to pharmaceutical compositions of the conjugate, and to methods for using the conjugate for target-specific delivery of v... | 08/16/2005 |
| 6872803 | Peptides The present invention provides peptides represented by the following formula (A): wherein Q represents a physiologically active peptide moiety; X each represents the same or different α-amino acid residue; M represent... | 03/29/2005 |
| 6852834 | Fusion peptides isolatable by phase transition Genetically-encodable, environmentally-responsive fusion proteins comprising ELP peptides. Such fusion proteins exhibit unique physico-chemical and functional properties that can be modulated as a function of solution environment. The invention also provides methods... | 02/08/2005 |
| 6770292 | Pharmaceutical compositions for oral administration A method for oral administration of an active principle includes the steps of incorporating an active principle in multilamellar vesicles having a diameter of between 0.1 and 25 μm, and a lamellar liquid-crystal internal structure formed, from the center to the per... | 08/03/2004 |
| 6716812 | Modulation of sperm function The hormone calcitonin promotes fertilizing ability in mammalian sperm and is useful for treatment of conditions of low fertility in humans and animals. Human, porcine or salmon calcitonin may be formulated in a pharmaceutical composition comprising a pharmaceutical... | 04/06/2004 |
| 6713452 | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same A mixture of conjugates in which each conjugate in the mixture comprises a calcitonin drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may lower serum calcium levels in a subject by 10, 15 or even 20 percent or more. M... | 03/30/2004 |
| 6673769 | Lanthionine bridged peptides Disclosed are lanthionine bridged peptides having the structure ##STR1## methods of their preparation and their use as pharmacologically active agents.... | 01/06/2004 |
| 6656922 | Oral delivery of macromolecules Polysaccharides, which are widely used as an anticoagulation drugs, especially heparin, are clinically administered only by intravenous or subcutaneous injection because of their strong hydrophilicity and high negative charge. Amphiphilic heparin derivati... | 12/02/2003 |
| 6617423 | Superpotent calcitonin analogs having greatly increased hypocalcemic action in vivo Calcitonins and calcitonin derivatives such as are employed for therapy for, for example, osteoporosis. Paget's disease or hypercalcemia. The calcitonins and calcitonin derivatives are distinguished by a bridging of the amino acids present in the position... | 09/09/2003 |
| 6605591 | Treatment of subnormal bone mineral density A method of treating an individual to increase the individual's bone mineral density (BMD) is disclosed. The method includes co-administering a calcitonin-like agent and a DHEA-like agent. Also disclosed are methods for potentiating the effect of treatmen... | 08/12/2003 |
| 6583114 | Fracture healing using pthrp analogs This invention provides methods of bone healing and fracture repair comprising administering to a patient in need thereof an effective amount of a polypeptide analog of parathyroid hormone related peptide (PTHrP) and salts thereof, wherein amino acid resi... | 06/24/2003 |
| 6576611 | Methods of reducing atrophy or dysfunction of gut-associated lymphoid tissue The present invention describes methods for reducing the impairment respiratory tract mucosal immunity associated with a lack of enteral feeding or a lack of immunological stimulation of the gastrointestinal tract comprising administering a therapeuticall... | 06/10/2003 |
| 6562946 | Human procalcitonin and the preparation and use thereof The invention relates to human procalcitonin and the preparation and use thereof. In particular, a process for preparing human procalcitonin is described wherein a gene coding for a polypeptide comprising the amino acid sequence of human procalcitonin is ... | 05/13/2003 |
| 6506730 | Nasal transmucosal delivery of peptide conjugated with biocompatible polymers The present invention relates to a pharmaceutical composition for the nasal transmucosal delivery of a biocompatible polymer-biologically active peptide conjugate. The pharmaceutical composition of the present invention increases the water solubility of p... | 01/14/2003 |
| 6462016 | Method for screening agonist or antagonist of the maxadilan receptor participating in vasodilating action, and compound found by the method There are provided a method to screen agonist or antagonist of the maxadilan receptor participating in vasodilating action, wherein a receptor of maxadilan is used, compounds which specifically bind to the receptor, and a tissue preparation having the rec... | 10/08/2002 |
| 6410707 | Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs A process for the recombinant preparation of a calcitonin fragment and the use of the fragment in the preparation of calcitonin and related analogs is provided. The process includes recombinantly forming a fusion protein which includes the calcitonin frag... | 06/25/2002 |
| 6319498 | Modulators of amyloid aggregation Compounds that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compo... | 11/20/2001 |
| 6284220 | Noninvasive imaging of nucleic acid vectors Nucleic acid-imaging compositions and methods for noninvasive imaging of a nucleic acid introduced into somatic tissues of an animal or human are disclosed. The noninvasive imaging enables quantitative assessment of the biodistribution of the introduced n... | 09/04/2001 |
| 6268339 | Lanthionine bridged peptides Disclosed are lanthionine bridged peptides having the structure ##STR1## methods of their preparation and their use as pharmacologically active agents.... | 07/31/2001 |
| 6268474 | Peptide antagonists of CGRP-receptor superfamily and methods of use This invention relates to antagonists of calcitonin gene related peptide and in particular the invention relates to amino terminal modifications to peptides to improve their ability to bind to a member of the CGRP-receptor superfamily.... | 07/31/2001 |
| 6265534 | Superpotent calcitonin analogs having greatly increased hypocalcemic action in vivo Superpotent calcitonin analogs have greatly increased hypocalcemic action in vivo. These calcitonins and calcitonin derivatives are employed for the therapy of, for example, osteoporosis, Paget's disease or hypercalcemia. The calcitonins and calcitonin de... | 07/24/2001 |
| 6251635 | Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs A process for the recombinant preparation of a calcitonin fragment and the use of the fragment in the preparation of calcitonin and related analogs is provided. The process includes recombinantly forming a fusion protein which includes the calcitonin frag... | 06/26/2001 |
| 6204256 | Acylated cyclodextrin derivatives A cyclodextrin derivative, wherein at least 60 percent of the free hydroxy groups of said cyclodextrin are acylated with acyl groups where at least one of said acyl groups comprise a free carboxylic group.... | 03/20/2001 |
| 6174857 | Composition and method for the treatment of osteoporosis in mammals Pharmaceutical compositions and methods for the treatment of osteoporosis in mammals are disclosed. The compositions are suitable for parenteral administration and comprise Insulin-Like Growth Factor I (IGF-I) and a pharmaceutically acceptable carrier. Th... | 01/16/2001 |
| 6127519 | Calcitonin derivatives Peptides useful in the regulation of calcium metabolism are disclosed. Also disclosed are pharmaceutical compositions of matter containing such peptides as well as a method for the regulation of calcium metabolism in a patient in need of such treatment. T... | 10/03/2000 |
| 6107277 | Calcitonin salmon analogues Salcatonin (i.e. salmon calcitonin) analogues of formula R1-Ser-Asn-Leu-Ser-Thr-Cys(SR2)-Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Ly s-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro-NH2 (I) are disclosed, in which R1=-Cys-S--H, -Cys--OH, -Cys-S-eth... | 08/22/2000 |
| 6093692 | Method and compositions for lipidization of hydrophilic molecules Fatty acid derivatives of disulfide-containing compounds (for example, disulfide-containing peptides or proteins) comprising fatty acid-conjugated products with a disulfide linkage are employed for delivery of the compounds to mammalian cells. This modifi... | 07/25/2000 |
| 6087338 | Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin The subject-matter of the invention are pharmaceutical non inorganic saline solutions for endonasal administration containing: (a) a calcitonin, preferably salmon or alternatively carbacalcitonin (elcatonin), or its pharmaceutically acceptable salts; char... | 07/11/2000 |
| 6083480 | Calcitonin receptor binding reagents This invention relates to radiotherapeutic reagents and peptides, radiodiagnostic reagents and peptides, and methods for producing labeled radiodiagnostic and radiotherapeutic agents. Specifically, the invention relates to calcitonin receptor binding comp... | 07/04/2000 |
